key: cord-1045503-rfw44hf9 authors: Kerget, Buğra; Kerget, Ferhan; Aksakal, Alperen; Aşkın, Seda; Sağlam, Leyla; Akgün, Metin title: Evaluation of alpha defensin, IL‐1 receptor antagonist, and IL‐18 levels in COVID‐19 patients with macrophage activation syndrome and acute respiratory distress syndrome date: 2020-10-30 journal: J Med Virol DOI: 10.1002/jmv.26589 sha: 13d9ec89f15a0464f2800c41c527fa7128f559c3 doc_id: 1045503 cord_uid: rfw44hf9 BACKGROUND: Many laboratory parameters have been associated with morbidity and mortality in SARS‐CoV‐2 (COVID‐19), which emerged in an animal market in Wuhan, China in December 2019 and has infected over 20 million people. This study investigated the relationship between serum interleukin (IL)‐18, IL‐1 receptor antagonist (IL‐1Ra), and alpha defensin levels and the clinical course and prognosis of COVID‐19. MATERIALS AND METHODS: This study included 100 patients who were admitted to the chest diseases department and intensive care unit of our hospital and diagnosed with COVID‐19 by real‐time polymerase chain reaction (PCR) of nasopharyngeal swab samples between March 24 and May 31, 2020. The control group consisted of 50 nonsymptomatic health workers with negative real‐time PCR results in routine COVID‐19 screening in our hospital. RESULTS: Serum alpha defensin, IL‐1Ra, and IL‐18 levels were significantly higher in patients who developed macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS) compared to patients who did not (p < .001 for all). Alpha defensin, IL‐1Ra, and IL‐18 levels were significantly higher in COVID‐19 patients with and without MAS or ARDS when compared to the control group (p < .001 for all). When the 9 patients who died were compared with the 91 surviving patients, IL‐1Ra and IL‐18 levels were found to be significantly higher in the nonsurvivors (p < .001). CONCLUSION: Our findings of correlations between alpha defensin and levels of IL‐1Ra and IL‐18, which were previously shown to be useful in COVID‐19 treatment and follow‐up, indicates that it may also be promising in treatment. To date, COVID-19 has infected over 20 million people worldwide since it appeared in December 2019, and case numbers continue to rise daily. Infected individuals may be asymptomatic or may exhibit mild symptoms such as fatigue, muscle, and joint pain, decreased appetite, and loss of smell and taste. However, the clinical presentation can be severe in certain individuals, especially older adults, people with hypertension, diabetes mellitus, or chronic kidney failure, patients receiving immunosuppressive therapy, and pregnant women. 1, 2 The main severe clinical manifestations of COVID-19 are acute respiratory failure and macrophage activation syndrome (MAS). In both presentations, excessive production of proinflammatory cytokines can cause endothelial dysfunction in many vital organs, especially the lungs. This state of intense cytokine discharge is known as a cytokine storm, and helper T cells are instrumental in its formation. Th-1 cells synthesize many of the major proinflammatory cytokines involved in the cytokine storm, particularly interleukin (IL)-1, IL-6, IL-12, and IL-17. Failure to maintain the pro-/anti-inflammatory balance is the most important cause of morbidity and mortality in patients with COVID-19. 3, 4 The proinflammatory side of this equilibrium also includes IL-18, which is a member of the IL-1 family and similar to IL-12 in its cytotoxic effect. In conjunction with IL-12, IL-18 stimulates interferongamma synthesis from natural killer cells and T cells, thereby activating the macrophages that play an important role in cellular immunity. 5 IL-18 dysregulation has been associated with several autoimmune and inflammatory diseases. 6,7 IL-1 receptor antagonist (IL-1Ra) is involved in the antagonization of IL-1, which plays an important role in the cytokine storm syndrome. An attenuated form of this protein is now able for use in patients with COVID-19 associated cytokine storm syndrome. 8 Alpha defensin is another cytokine that helps prevent the excessive cytokine response from macrophages that contributes to the cytokine storm. Alpha defensin is a protein mainly synthesized by apoptotic and necrotic neutrophils as a part of the innate immune defense against viral and bacterial infections. 9 Studies have shown that alpha defensin has an important role in preventing virus entry into cells and in the transmission of viral infection between cells. This antiviral effect has been interpreted as evidence that it may be used as a part of treatment to prevent and control viral infections. 9, 10 The aim of this study was to investigate the relationships between clinical course, prognosis, and mortality in COVID-19 patients and their levels of IL-18, IL-1Ra, and alpha defensin, which are important players in the inflammatory/anti-inflammatory balance in viral infections. The study included patients who presented to the emergency department of Atatürk University with suspicious symptoms such as fever, cough, dyspnea, fatigue, and sudden loss of smell and taste and had a history of travel abroad or contact with a suspected COVID-19 patient within the past 14 days. High-resolution computed tomography (HRCT) was performed routinely in all patients at high risk for COVID-19. Patients whose HRCT results suggested COVID-19 and those whose radiologic findings were atypical but had consistent clinical symptoms were admitted. COVID-19 diagnosis was established by real-time polymerase chain reaction (PCR) testing of nasopharyngeal swab samples. The study group comprised 121 patients who were followed up in the chest diseases department between March 24, 2020 (the date of admission of the first COVID-19-positive patient to Atatürk University) and May 31, 2020. The control group consisted of 50 nonsymptomatic health workers in our hospital who tested negative in routine real-time PCR screening for COVID-19. As inflammatory dysregulation is more common in COVID-19 patients with comorbidities, for our study focusing on inflammatory parameters, we excluded 10 patients presenting with uncontrolled diabetes mellitus, two patients who presented with COVID-19 and concomitant acute coronary syndrome, one patient with COVID-19 and concomitant infarction in the temporoparietal region, and eight patients who were active smokers. Following admission, the patients' hematological parameters, biochemical parameters including liver and kidney function tests, coagulation parameters, ferritin, D-dimer, troponin-I, C-reactive protein (CRP), and arterial blood gas parameters were examined. Fever was defined as an axillary temperature of 37.3°C or higher. Patients who did not show significant improvement in laboratory parameters and vital signs after 24 h were given another dose of 400 mg tocilizumab. After 15 min of semi-supine rest, blood samples were collected from the antecubital vein into tubes containing ethylenediaminetetraacetic acid to prevent coagulation. Troponin-I concentrations were measured by a chemiluminescent immunoassay using an Immulite 2500 (Siemens Medical Solutions). Alpha defensin, IL-1Ra, and IL-18 levels were measured by enzyme-linked immunosorbent assay (Elabscience Human ELISA Kit). The data were analyzed using IBM SPSS Statistics for Windows version 24.0 (IBM Corp.). Pearson's χ 2 test and Mann-Whitney U test were used for intergroup comparisons of parametric data and nonnormally distributed numerical data, respectively. An independentsamples t-test was used to compare demographic data and laboratory parameters between groups. Analysis of variation was used to compare levels of alpha defensin, IL-1Ra, and IL-18 between patient groups with and without MAS and ARDS and the control group. Pearson's correlation analysis was used to evaluate relationships between laboratory parameters. A p-value of less than .05 was considered statistically significant. Of the 100 patients with COVID-19 included in the study, 55 were women and 45 were men. The control group comprised of 25 men and 25 women. The mean age of the female patients with COVID-19 was 46.2 ± 19.1 years and that of the male patients was 51.9 ± 21.5 years. There was no statistically significant difference in mean age according to sex (p = .171). The mean age of the participants in the control group was 49.2 ± 17.6 years. There was no statistically significant difference in age between the patient and control groups (p = .09). In the COVID- 19 In this study, we determined that alpha defensin, IL-1Ra, and IL-18 levels were elevated in patients with COVID-19. We also observed that this elevation was more pronounced in patients with MAS and ARDS compared with those without. In addition, IL-1Ra and IL-18 levels were higher in nonsurvivors compared to surviving patients. In addition, it has also been found to minimize oxidative damage while increasing viral uptake. 19 In a study conducted on animals infected with Pseudomonas aeruginosa, it was found that alpha defensin synthesized by apoptotic and necrotic neutrophils led to a decrease in levels of TNF-α, IL-1 beta, IL-6, and IL-8, which are important proinflammatory cytokines. 20 Consistent with previous SARS-CoV-2 studies, we observed in the present study that prothrombin time, PaO 2 /FiO 2 , and levels of CRP, Troponin-I, D-dimer, and ferritin, which are known to be associated with morbidity and mortality, were relatively higher during hospitalization in patients who developed MAS and ARDS than those who did not. Furthermore, the older age of these patients again demonstrates the importance of age as a risk factor in the COVID-19 pandemic. The present study focused on alpha defensin, IL-1Ra, and IL-18 levels and showed that these are also higher in patients who The most important limitation of the present study was that the patients who developed MAS and ARDS were older and had more comorbidities. However, the fact that SARS-CoV-2 causes higher morbidity and mortality especially in older adults and those with chronic diseases may complicate attempts to form study groups that are homogeneous in terms of age and comorbidities. In conclusion, with a steady stream of new information about its diagnosis and treatment and no sign of it losing virulence, the treatment of COVID-19 remains an important issue today. Alpha defensin has been shown to have anti-inflammatory activity in viral infections such as influenza A and SARS-CoV, and its elevation in correlation with agents used in the diagnosis and treatment of patients infected with SARS-CoV-2 may be a new beacon of hope for treatment. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19: immunopathology and its implications for therapy IL-1, IL-18, and IL-33 families of cytokines IL-18 in autoimmunity Serum IL-18 levels in tuberculosis: comparison with pneumonia, lung cancer and healthy controls In the eye of the COVID-19 cytokine storm Defensins in viral infection and pathogenesis Alpha-defensin-dependent enhancement of enteric viral infection A review of coronavirus disease-2019 (COVID-19) COVID-19 severity correlates with airway epithelium-immune cell interactions identified by singlecell analysis On the alert for cytokine storm: immunopathology in COVID-19 Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome Immunomodulation in COVID-19 Antiviral mechanisms of human defensins Human α defensin in HIVexposed but uninfected individuals β-defensin inhibits influenza virus replication by cell-mediated mechanism (s) Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses Human defensins Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome The authors declare that there are no conflict of interests. Conceptualization, methodology, software, validation, and formal analy- The data that support the findings of this study are available from the corresponding author upon reasonable request.